|Bid||13.50 x 900|
|Ask||18.00 x 800|
|Day's range||16.22 - 16.87|
|52-week range||11.75 - 23.64|
|Beta (5Y monthly)||1.58|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||38.17|
We can readily understand why investors are attracted to unprofitable companies. Indeed, Spero Therapeutics...
Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Under the guidance of CEO Ankit Mahadevia, Spero Therapeutics, Inc. ( NASDAQ:SPRO ) has performed reasonably well...